Households exposed to COVID-19 now have an oral drug specifically cleared to prevent infection after contact with a sick ...

NCCN now recommends pemivibart pre-exposure prophylaxis for patients with B-cell lymphomas and other profoundly ...

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older. Xocova is ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...

Please provide your email address to receive an email when new articles are posted on . The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention ...

Xocova is a 5-day oral regimen with 3 tablets taken as a single dose on day 1 then 1 tablet taken on days 2 through 5. Compared with placebo, ensitrelvir significantly reduced the risk of symptomatic ...